Complementary anti-cancer pathways triggered by inhibition of sideroflexin 4 in ovarian cancer

Abstract DNA damaging agents are a mainstay of standard chemotherapy for ovarian cancer. Unfortunately, resistance to such DNA damaging agents frequently develops, often due to increased activity of DNA repair pathways. Sideroflexin 4 (SFXN4) is a little-studied inner mitochondrial membrane protein....

Full description

Bibliographic Details
Main Authors: Lia Tesfay, Bibbin T. Paul, Poornima Hegde, Molly Brewer, Samrin Habbani, Evan Jellison, Timothy Moore, Hao Wu, Suzy V. Torti, Frank M. Torti
Format: Article
Language:English
Published: Nature Portfolio 2022-11-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-24391-3